Bergmann Joshua Benjamin 4
4 · GYRE THERAPEUTICS, INC. · Filed Jun 10, 2026
Research Summary
AI-generated summary of this filing
Gyre Therapeutics GC Joshua Bergmann Receives 50,000-Share Award
What Happened
Joshua Benjamin Bergmann, General Counsel and Corporate Secretary of Gyre Therapeutics (GYRE), was granted a derivative award on 2026-06-08 representing the right to purchase 50,000 shares of the company's common stock. The filing lists the acquisition price as $0.00 and shows the award as a derivative (code A — grant/award).
Key Details
- Transaction date: 2026-06-08; Form 4 filed 2026-06-10 (timely under the two-business-day rule).
- Security: Option/right to purchase 50,000 shares; price shown in filing: $0.00.
- Vesting (from filing footnote): 25% vests on June 8, 2027; remaining 75% vests in equal monthly installments over the next three years, subject to continued service.
- Shares owned after the transaction: not specified in the filing.
- Transaction type: Award/grant (derivative); not an open-market purchase or sale.
Context
This is a compensation award (an option/right) rather than a market purchase or sale. Such grants are routine for executive compensation and do not by themselves signal intent to buy or sell shares on the open market. The option's terms (exercise price and any tax withholding method beyond the listed $0.00) are not further detailed in the filing.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-08+50,000→ 50,000 totalExercise: $6.05Exp: 2036-06-08→ Common Stock (50,000 underlying)
Footnotes (1)
- [F1]This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.